0A23 Stock Chart & Stats
$28.50
$0.00(0.00%)
At close: 4:00 PM EDT
$28.50
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$28.50 - $28.50
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
$663.24M
Enterprise Value$589.25
Total Cash (Recent Filing)$74.71M
Total Debt (Recent Filing)$92.56M
Price to Earnings (P/E)70.5
Beta0.93
Next Earnings
Sep 09, 2026EPS Estimate
0.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.15
Shares Outstanding61,811,890
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-3.35
Price to Book (P/B)2.38
Price to Sales (P/S)1.67
P/FCF Ratio11.85
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$14.00Price Target Upside-50.88% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering13
EPS Forecast (FY)0.4
Revenue Forecast (FY)$515.15M
Bulls Say, Bears Say
Bulls Say
Cash GenerationPhreesia has converted earnings into cash effectively: TTM operating cash flow of $87.9M and FCF of $76.0M (≈19% FCF growth). Free cash flow running at ~86% of net income provides durable funding for operations, de‑risking near‑term liquidity and enabling reinvestment or deleveraging.
Profitability Inflection And Margin ExpansionThe company has moved to consistent profitability with three consecutive quarters of positive net income and a 23% adjusted EBITDA margin in Q1. This demonstrates operating leverage and suggests sustainable earnings power if cost initiatives and revenue mix gains (Payment and Network Solutions) persist over the medium term.
Enhanced Liquidity And Financing FlexibilityRefinancing into a $275M revolver and expanding PNC securitization to $300M materially improve funding optionality, support Access One integration, and lower rollover risk. Greater committed liquidity increases resilience to operating variability and underpins strategic investments over the next several quarters.
Bears Say
Subscription Revenue SoftnessA sequential ~6% decline in subscription revenue signals pressure in the core provider recurring business. If sustained, lower subscription trends would weaken the recurring revenue base, reduce upsell leverage, and make achieving mid‑single digit AHSC and per‑client growth targets more difficult over the coming quarters.
Thin Operating MarginsDespite a profitability turn, operating margins remain slim (TTM EBIT ~0.2%, EBITDA ~6.5%), leaving limited buffer against revenue softness or higher costs. Sustaining margin expansion depends on successful realization of restructuring savings and scale benefits; failure to execute would quickly compress earnings and cash generation.
Network Solutions Revenue VariabilityManagement noted increased variability and lower client commitments in Network Solutions for H2, reducing revenue visibility. This structural unpredictability can impair forward booking, complicate resource planning, and increase the likelihood of shortfalls versus guidance absent stronger, more consistent client program demand.
Phreesia News
0A23 FAQ
What was Phreesia’s price range in the past 12 months?
Phreesia lowest share price was $28.50 and its highest was $28.50 in the past 12 months.
What is Phreesia’s market cap?
Phreesia’s market cap is $663.24M.
When is Phreesia’s upcoming earnings report date?
Phreesia’s upcoming earnings report date is Sep 09, 2026 which is in 36 days.
How were Phreesia’s earnings last quarter?
Phreesia released its earnings results on May 27, 2026. The company reported $0.05 earnings per share for the quarter, beating the consensus estimate of $0.011 by $0.039.
Is Phreesia overvalued?
According to Wall Street analysts Phreesia’s price is currently Overvalued.
Does Phreesia pay dividends?
Phreesia does not currently pay dividends.
What is Phreesia’s EPS estimate?
Phreesia’s EPS estimate is 0.09.
How many shares outstanding does Phreesia have?
Phreesia has 61,811,890 shares outstanding.
What happened to Phreesia’s price movement after its last earnings report?
Phreesia reported an EPS of $0.05 in its last earnings report, beating expectations of $0.011. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Phreesia?
Currently, no hedge funds are holding shares in GB:0A23
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Phreesia Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$14.00 (-50.88% Downside)
$14.00 (-50.88% Downside)
Blogger Sentiment
Neutral
GB:0A23 Sentiment 50%
Sector Average ―
Sector Average ―
Technicals
SMA
Negative
20 days / 200 days
Momentum
-62.21%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
66.37%
Trailing 12-Months
Company Description
Phreesia
Phreesia, Inc. offers a comprehensive, cloud-based software-as-a-service (SaaS) and payment platform specifically designed for the healthcare industry in the United States and Canada. Its flagship Phreesia Platform streamlines the patient intake process and facilitates integrated patient payment processing. The platform is accessible via multiple modalities, including Phreesia Mobile (a patient-facing mobile application), Phreesia Dashboard (a web-based portal for healthcare clients), self-service tablets known as PhreesiaPads, and on-site Arrivals Kiosks. The Phreesia Platform integrates a suite of specialized modules: An automated patient self-registration system. A revenue cycle management solution providing insurance verification, point-of-sale payment applications, and cost estimation tools. Access solutions for online appointment scheduling, reminders, and referral tracking. A life sciences solution delivering targeted, clinically relevant marketing content to patients. Additionally, a clinical support solution gathers clinical intake and patient-reported outcome (PRO) data across approximately 25 specialties, and enables healthcare clients to communicate with patients via surveys, announcements, text and email messaging, and health campaigns. Dedicated COVID-19 support modules assist with vaccine delivery management, identifying vaccine-hesitant individuals, screening for risk factors, facilitating contactless check-in, and managing telehealth visit intake. Phreesia serves a diverse clientele, including individual patients; single and multi-specialty practices, along with health systems; and pharmaceutical, medical device, and biotechnology firms. Established in 2005, the company maintains its headquarters in Raleigh, North Carolina.
0A23 Company Deck
0A23 Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented multiple clear operating and financial positives: solid top-line growth (+13% YoY), strong adjusted EBITDA improvement (+~46% YoY) and a return to net income, improved operating and free cash flow, enhanced liquidity via refinancing and a larger securitization facility for Access One, and maintained full-year guidance. Headwinds included a sequential decline in subscription revenue, higher variability and lower-than-expected client commitments in Network Solutions for the back half of the year, and some dependence of Payment Solutions growth on the recent Access One acquisition. On balance, the positive operational and financial momentum, maintaining guidance, and strategic financing and product initiatives outweigh the listed challenges.View all GB:0A23 earnings summaries0A23 Revenue Breakdown
45.91% Subscription and related services
27.90% Payment processing fees
26.19% Network solutions
0A23 Stock 12 Month Forecast
Average Price Target
$14.00
▼(-50.88% Downside)
Technical Analysis
CareCloud
―
Evolent Health
―
Health Catalyst
―
American Well
―
Waystar Holding Corp.
―